BRPI0719937A2 - Pró-fármacos e métodos de fazer e de usar os mesmos - Google Patents

Pró-fármacos e métodos de fazer e de usar os mesmos

Info

Publication number
BRPI0719937A2
BRPI0719937A2 BRPI0719937-6A2A BRPI0719937A BRPI0719937A2 BR PI0719937 A2 BRPI0719937 A2 BR PI0719937A2 BR PI0719937 A BRPI0719937 A BR PI0719937A BR PI0719937 A2 BRPI0719937 A2 BR PI0719937A2
Authority
BR
Brazil
Prior art keywords
pro
drugs
making
methods
same
Prior art date
Application number
BRPI0719937-6A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Naweed Muhammad
Keith R Bley
Original Assignee
Neurogesx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogesx Inc filed Critical Neurogesx Inc
Publication of BRPI0719937A2 publication Critical patent/BRPI0719937A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D225/00Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0719937-6A2A 2006-12-05 2007-12-05 Pró-fármacos e métodos de fazer e de usar os mesmos BRPI0719937A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87351906P 2006-12-05 2006-12-05
PCT/US2007/024984 WO2008070149A2 (en) 2006-12-05 2007-12-05 Prodrugs and methods of making and using the same

Publications (1)

Publication Number Publication Date
BRPI0719937A2 true BRPI0719937A2 (pt) 2014-03-11

Family

ID=39361296

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719937-6A2A BRPI0719937A2 (pt) 2006-12-05 2007-12-05 Pró-fármacos e métodos de fazer e de usar os mesmos

Country Status (12)

Country Link
US (1) US20080318905A1 (enExample)
EP (1) EP2121029A2 (enExample)
JP (1) JP2010511717A (enExample)
KR (1) KR20090086627A (enExample)
CN (1) CN101678120A (enExample)
AU (1) AU2007328007A1 (enExample)
BR (1) BRPI0719937A2 (enExample)
CA (1) CA2671737A1 (enExample)
MX (1) MX2009006007A (enExample)
NO (1) NO20092527L (enExample)
RU (1) RU2009125597A (enExample)
WO (1) WO2008070149A2 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
CN101622263B (zh) * 2007-03-06 2013-05-29 卫材R&D管理有限公司 稳定性被改善的含有磷酸氯甲酯衍生物的组合物及其制备方法
TW200841879A (en) 2007-04-27 2008-11-01 Eisai R&D Man Co Ltd Pyridine derivatives substituted by heterocyclic ring and phosphonoamino group, and anti-fungal agent containing same
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
CA2724881C (en) 2008-05-20 2016-09-27 Neurogesx, Inc. Carbonate prodrugs and methods of using the same
WO2009143299A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
CN105254662A (zh) 2008-05-20 2016-01-20 阿索尔达治疗公司 水溶性对乙酰氨基酚类似物
WO2010013158A1 (en) 2008-07-28 2010-02-04 Pfizer Inc. Phenanthrenone compounds, compositions and methods
US20100076198A1 (en) * 2008-09-19 2010-03-25 Mallinckrodt Inc. Crystalline forms of Fentanyl Alkaloid
NZ597108A (en) * 2009-06-25 2014-04-30 Alkermes Pharma Ireland Ltd Prodrugs of nh-acidic compounds
SMT201700430T1 (it) 2009-06-25 2018-01-11 Alkermes Pharma Ireland Ltd Composti eterociclici per il trattamento di disturbi neurologici e psicologici
CA2802733C (en) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
HUE032109T2 (en) 2011-03-18 2017-08-28 Alkermes Pharma Ireland Ltd Injectable pharmaceutical compositions containing water insoluble antipsychotic, sorbitan laurate and polysorbate 20
BR112014002084B1 (pt) * 2011-07-28 2022-03-29 Kempharm, Inc Composição de pró-fármaco e uso de conjugado de metilfenidato
US9024055B2 (en) 2011-09-22 2015-05-05 Acorda Therapeutics, Inc. Acetaminophen conjugates, compositions and methods of use thereof
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
WO2013142205A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
WO2014172482A1 (en) 2013-04-17 2014-10-23 Robert Alfred Volkmann Compounds for treatment of pain
US10072018B2 (en) 2013-04-17 2018-09-11 Biopharma Works Compounds for treatment of pain
EP3004115B1 (en) 2013-05-24 2019-03-06 Rhodes Technologies Opioid ketal compounds and uses thereof
ES2784690T3 (es) 2013-12-05 2020-09-29 Univ Bath Nuevos compuestos opioides y sus usos
WO2015143145A1 (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
CN108135864A (zh) * 2015-05-13 2018-06-08 4P-制药公司 兴奋剂防滥用组合物
US20170273974A1 (en) * 2016-03-24 2017-09-28 Medrx Co., Ltd Patch preparations with misuse prevention features
WO2019086017A1 (en) * 2017-11-03 2019-05-09 Nirsum Laboratories, Inc. Opioid receptor antagonist prodrugs
US11845759B2 (en) 2018-02-23 2023-12-19 Rhodes Technologies Opioid compounds and uses thereof
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US10799496B2 (en) 2018-07-13 2020-10-13 Alkermes Pharma Ireland Limited Naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020077038A1 (en) * 2018-10-13 2020-04-16 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs of cgrp antagonists
US10975099B2 (en) 2018-11-05 2021-04-13 Alkermes Pharma Ireland Limited Thiophene compounds for long-acting injectable compositions and related methods
WO2020227337A1 (en) * 2019-05-07 2020-11-12 Bristol-Myers Squibb Company Prodrug compounds
FI130262B (en) * 2019-08-30 2023-05-17 Medicortex Finland Oy Formulations and compositions for use in the prevention or treatment of brain injury and neurodegenerative diseases
AU2020360928A1 (en) * 2019-09-30 2022-04-14 Nippon Chemiphar Co., Ltd. Azepan derivative
CN114380859B (zh) * 2020-10-22 2024-11-01 威智医药股份有限公司 磷酸二苄酯及焦磷酸四苄酯的制备方法
CN117805249A (zh) * 2022-09-23 2024-04-02 合肥瀚微生物科技有限公司 一种抑郁症诊断的生物标记物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
PT1685839E (pt) * 1997-12-22 2013-07-08 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
CA2317008C (en) * 1997-12-31 2009-01-20 The University Of Kansas Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
ATE454169T1 (de) * 2003-03-13 2010-01-15 Controlled Chemicals Inc Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
EP3326617A1 (en) * 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations

Also Published As

Publication number Publication date
RU2009125597A (ru) 2011-01-20
EP2121029A2 (en) 2009-11-25
JP2010511717A (ja) 2010-04-15
KR20090086627A (ko) 2009-08-13
WO2008070149A3 (en) 2009-12-10
NO20092527L (no) 2009-09-04
MX2009006007A (es) 2009-07-17
AU2007328007A1 (en) 2008-06-12
CN101678120A (zh) 2010-03-24
CA2671737A1 (en) 2008-06-12
US20080318905A1 (en) 2008-12-25
WO2008070149A2 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
BRPI0719937A2 (pt) Pró-fármacos e métodos de fazer e de usar os mesmos
DK1720866T3 (da) Fremgangsmåde
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
ATE528296T1 (de) Polymorphe form von 4-ä3-(4- cyclopropancarbonylpiperazin-1-carbonyl)-4- fluorbenzylü-2h-phthalazin-1-on
CR10562A (es) Nuevos derivados de piridazina
EP1967696A4 (en) TURBINE PART
EP2211714A4 (en) PROOF OF IMPEDANCE
BRPI0720601A2 (pt) Misturas de corantes dispersos
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
FR2908130B1 (fr) Flottage de vitroceramique
JP2006122056A5 (ja) β-グルカンの使用
BRPI0813116A2 (pt) Tornozeleira e kit de tornozeleira
FI20065757L (fi) Beta-laktamaasin käyttö
CR10430A (es) Aminothiazoles and their uses
ES1064635Y (es) Disposicion de conjuntos conmutadores de pulsador
DK2004815T3 (da) Funktional ekspression af triacylglycerol-lipaser
EP1906944A4 (en) SKI ANDRIN-B-PREPARATION
NO20055643D0 (no) Preparation of lodixanol
PT1763520E (pt) Utilização de benzopiranonas trissubstituídas
DK2173197T3 (da) Fremgangsmåde
EP1750710A4 (en) NEUROPROTECTIVE PROPERTIES OF ROTATING MORPHINANES
DOP2006000261A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos
EP1888237A4 (en) OUTPUT SEQUENCE FOR TURNING DEVICE
FR2896995B1 (fr) Raquette de paddleball
FR2877833B1 (fr) Correcteur de lordoses

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 5A E 6A ANUIDADES.

B15K Others concerning applications: alteration of classification

Ipc: A61K 47/54 (2017.01)

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A, 9A, 10A, 11A E 12A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.